The stock price of SI-BONE Inc (NASDAQ: SIBN) has surged by 1.89 when compared to previous closing price of 18.49, but the company has seen a -0.74% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-04 that SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 17, 2025, at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.
Is It Worth Investing in SI-BONE Inc (NASDAQ: SIBN) Right Now?
The 36-month beta value for SIBN is also noteworthy at 0.95. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SIBN is 36.95M, and at present, short sellers hold a 4.38% of that float. The average trading volume of SIBN on June 05, 2025 was 429.64K shares.
SIBN’s Market Performance
The stock of SI-BONE Inc (SIBN) has seen a -0.74% decrease in the past week, with a 14.53% rise in the past month, and a 15.16% gain in the past quarter. The volatility ratio for the week is 1.06%, and the volatility levels for the past 30 days are at 2.53% for SIBN. The simple moving average for the past 20 days is 0.02% for SIBN’s stock, with a 24.35% simple moving average for the past 200 days.
Analysts’ Opinion of SIBN
Many brokerage firms have already submitted their reports for SIBN stocks, with Needham repeating the rating for SIBN by listing it as a “Buy.” The predicted price for SIBN in the upcoming period, according to Needham is $19 based on the research report published on August 06, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see SIBN reach a price target of $25. The rating they have provided for SIBN stocks is “Overweight” according to the report published on March 28th, 2024.
Jefferies gave a rating of “Buy” to SIBN, setting the target price at $20 in the report published on October 12th of the previous year.
SIBN Trading at 18.21% from the 50-Day Moving Average
After a stumble in the market that brought SIBN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.03% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at SIBN starting from FRANCIS LAURA, who sale 12,385 shares at the price of $19.67 back on May 16 ’25. After this action, FRANCIS LAURA now owns 495,170 shares of SI-BONE Inc, valued at $243,670 using the latest closing price.
FRANCIS LAURA, the Chief Executive Officer of SI-BONE Inc, sale 5,412 shares at $19.49 during a trade that took place back on May 19 ’25, which means that FRANCIS LAURA is holding 490,987 shares at $105,464 based on the most recent closing price.
Stock Fundamentals for SIBN
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.79 for the gross margin
The net margin for SI-BONE Inc stands at -0.15. The total capital return value is set at -0.15. Equity return is now at value -15.96, with -11.77 for asset returns.
Based on SI-BONE Inc (SIBN), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -9.53.
Currently, EBITDA for the company is -23.09 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 4.54. The receivables turnover for the company is 6.61for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.53.
Conclusion
In summary, SI-BONE Inc (SIBN) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
